VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Monday. The brokerage issued a sell rating on the stock.

Other research analysts have also issued research reports about the stock. HC Wainwright began coverage on shares of VolitionRx in a research note on Tuesday, April 8th. They issued a “buy” rating and a $2.50 price objective for the company. D. Boral Capital restated a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $3.33.

VolitionRx Stock Performance

Shares of NYSE VNRX opened at $0.48 on Monday. The stock has a market capitalization of $48.36 million, a PE ratio of -1.33 and a beta of 1.15. VolitionRx has a twelve month low of $0.42 and a twelve month high of $1.02. The stock has a fifty day simple moving average of $0.55 and a 200-day simple moving average of $0.61.

Insider Activity at VolitionRx

In other VolitionRx news, CEO Cameron John Reynolds bought 181,818 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The shares were purchased at an average price of $0.55 per share, with a total value of $99,999.90. Following the completion of the acquisition, the chief executive officer now directly owns 2,299,222 shares of the company’s stock, valued at $1,264,572.10. This represents a 8.59 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 12.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in VNRX. Lagoda Investment Management L.P. boosted its holdings in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after buying an additional 95,900 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after buying an additional 28,579 shares in the last quarter. Millennium Management LLC purchased a new position in shares of VolitionRx in the 4th quarter valued at $36,000. Finally, Two Sigma Securities LLC acquired a new stake in VolitionRx during the 4th quarter worth $29,000. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.